In recent years researchers have turned to transient gene expression (TGE) as an alternative to CHO stable cell line production for early stage antibody development. Despite advances in transfection methods and culture optimization, the majority of CHO-based TGE systems produce insufficient antibody titers (low mg/L level) for full use within the biotherapeutic development pipelines. MaxCyte’s delivery platform for cell engineering is based on Flow Electroporationâ„¢ technology and provides a universal means of fully scalable, highly efficient CHO-based TGE for the…